西洛他唑可降低股腘动脉经皮腔内血管成形术后靶病变的血管再通率。

Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery.

作者信息

Iida Osamu, Nanto Shinsuke, Uematsu Masaaki, Morozumi Takakazu, Kotani Jun-Ichi, Awata Masaki, Onishi Toshinari, Ito Noriaki, Oshima Fusako, Minamiguchi Hitoshi, Kitakaze Masafumi, Nagata Seiki

机构信息

Kansai Rosai Hospital, Amagasaki, Japan.

出版信息

Circ J. 2005 Oct;69(10):1256-9. doi: 10.1253/circj.69.1256.

DOI:10.1253/circj.69.1256

PMID:16195627

Abstract

BACKGROUND

Although percutaneous transluminal angioplasty (PTA) is being widely used for the treatment of stenosis of peripheral arteries, the high in-stent restenosis rate (50-60%) in the femoropopliteal artery still remains an unsolved issue. Cilostazol is a unique antiplatelet drug that has vasodilatory effects and inhibits smooth muscle cell proliferation.

METHODS AND RESULTS

A total of 141 consecutive patients scheduled for PTA in the femoropopliteal artery between September 1999 and April 2004 were retrospectively analyzed for the use of cilostazol. Target lesion revascularization (TLR) was defined as repeated PTA in patients who had a recurrence of symptoms with diameter stenosis >50% by angiography. Patient and lesion characteristics were similar between the cilostazol (+) and cilostazol (-) groups. Use of other medications was similar between the groups, except for ticlopidine, which was more frequently used in the cilostazol (-) than in the cilostazol (+) group (15% vs 61%, p<0.01). TLR was significantly reduced in the cilostazol (+) group (12% [8/68] vs 32% [23/73], p<0.01).

CONCLUSIONS

Although this study was retrospective and nonrandomized, the results suggest that cilostazol reduces TLR after PTA in the femoropopliteal artery.

摘要

背景

尽管经皮腔内血管成形术（PTA）被广泛用于治疗外周动脉狭窄，但股腘动脉支架内再狭窄率高（50 - 60%）仍是一个未解决的问题。西洛他唑是一种独特的抗血小板药物，具有血管舒张作用并抑制平滑肌细胞增殖。

方法与结果

回顾性分析了1999年9月至2004年4月期间计划在股腘动脉进行PTA的141例连续患者使用西洛他唑的情况。靶病变血管重建（TLR）定义为血管造影显示直径狭窄>50%且症状复发的患者再次进行PTA。西洛他唑（+）组和西洛他唑（-）组的患者和病变特征相似。除噻氯匹定外，两组间其他药物的使用情况相似，噻氯匹定在西洛他唑（-）组中的使用频率高于西洛他唑（+）组（15%对61%，p<0.01）。西洛他唑（+）组的TLR显著降低（12% [8/68]对32% [23/73]，p<0.01）。